Tecentriq lands FDA approval as adjuvant treatment for muscle invasive bladder cancer

The FDA has approved atezolizumab and atezolizumab with hyaluronidase-tqjs as adjuvant treatment for certain adults with muscle invasive bladder cancer. Atezolizumab (Tecentriq, Genentech) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) received approval as adjuvant treatments after cystectomy for adults with circulating tumor DNA molecular residual disease, as